Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
VGB-Ex01 by Shanghai Vitalgen BioPharma for Beta Thalassaemia: Likelihood of Approval
VGB-Ex01 is under clinical development by Shanghai Vitalgen BioPharma and currently in Phase II for Beta Thalassaemia. According to GlobalData,...